Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

BACKGROUND: Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma (mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence comparing sequencing strategies, and available comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Géczi, Lajos, Bodoky, György, Rokszin, György, Fábián, Ibolya, Torday, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471136/
https://www.ncbi.nlm.nih.gov/pubmed/32291570
http://dx.doi.org/10.1007/s12253-020-00809-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471136/
https://www.ncbi.nlm.nih.gov/pubmed/32291570
http://dx.doi.org/10.1007/s12253-020-00809-z

Ejemplares similares